Jessie Lin

Jessie is a multidisciplinary leader with over a dozen years of experience across the life sciences industry, specializing in strategic growth initiatives and corporate communications. Jessie joined the Nuvalent team in September 2021 as Vice President of Corporate Strategy and Portfolio Management.

Before joining Nuvalent in this role, Jessie was an independent consultant working closely with the Nuvalent team through its emergence from stealth, Series B financing, and upsized IPO. Prior to this, Jessie was Director, Strategic Planning & Communications at Verastem Oncology. In this role, she led transformative business development, regulatory, and patient advocacy initiatives which enabled the pivot from an early-stage biotech to a commercial stage oncology company with an FDA approved product in just 3 years. Following the FDA approval of COPIKTRA®, Jessie served as alliance manager for development and commercialization collaborations in China and Japan. Prior to Verastem Oncology, Jessie held roles at Human Care Systems, an agency specializing in developing patient adherence programs for marketed products, Scientia Advisors, a boutique life science strategic consulting firm, and On-Q-ity, a precision oncology start-up developing predictive diagnostics using circulating tumor cells.

Jessie earned her bachelor’s degree in bioengineering as a member of the founding four classes at the Franklin W. Olin College of Engineering.